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Background: Patients receiving anticoagulant drugs must be carefully screened for drug-related problems, as such
medications, including warfarin have narrow therapeutic ranges and a high potential for complications. Thus, this
study was designed to assess drug-related problems in the management of patients with deep vein thrombosis at
Tikur Anbessa Specialized Hospital.
Methods: A cross-sectional descriptive study involving retrospective chart review of adult patients with deep vein
thrombosis was conducted from patients who visited the hospital from July 2012 to June 2013, using structured
data collection format and this was complemented by key informant interview.
Results: The study included 91 patients with venous thromboembolism. Fifty three (58.2 %) were females. Mean
age was 38.6 (±13.76) years and more than 2/3 were below the age of 44 years. About 54 % of them presented
with concurrent medical conditions and most commonly with cancer. Adjustment of warfarin dose up or down
was done in increments of 16 to 100 % for recent subtherapeutic International Normalized Ratios, 16 to 50 % for
therapeutic and 11 to 66 % for overtherapeutic International Normalized Ratios, with the mean of 36.5 (±18.03)
based on the cumulative weekly dose of warfarin. There was significant linear relationship between percentage of
dose change and consequent International Normalized Ratio values (R2 = 0.419; p = 0.000). Accordingly, more than
51 % of them presented with nontherapeutic International Normalized Ratio ranges following dose adjustment.
Conclusions: The most prevalent anticoagulation drug-related problems were subtherapeutic doses, overtherapeutic
doses and potential drug interactions. Institutional validated decision support tools for dosing decisions during
maintenance anticoagulation therapy should be developed and used accordingly in order to prevent recurrent and
hemorrhagic complications and to improve clinical outcomes.
Keywords: Deep vein thrombosis, Drug-related problems, Warfarin, International Normalized Ratio, Tikur Anbessa
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A drug-related problem (DRP) is defined as an event or
circumstance involving drug therapy that actually or
potentially interferes with desired health outcomes.
Categories of DRPs include unnecessary drug therapy,
the needs for additional drug therapy, ineffective drug,
dosage too low, dosage too high, adverse drug reaction
(ADR) and patient noncompliance to the treatment [1].* Correspondence: fekedeb2@gmail.com
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(http://creativecommons.org/publicdomain/zeDRPs are frequent and may result in reduced quality
of life, and even morbidity and mortality. Despite excel-
lent benefits and safety profile of most medications,
DRPs pose a significant risk to patients, which adversely
affect quality of life, increase hospitalization and overall
health care cost. DRPs may arise at all stages of the
medication process from prescription to follow-up of
treatment [2].
Deep vein thrombosis (DVT) is the development of
single or multiple blood clots within the deep veins of the
extremities or pelvis, usually accompanied by inflamma-
tion of the vessel wall. The major clinical consequence iss distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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for thrombosis include a prior thrombotic event, recent
major surgery, presence of a central venous catheter,
trauma, immobilization, malignancy, pregnancy, use of
oral contraceptives, myeloproliferative disorders, and
antiphospholipid syndrome.
It has long been known that hypercoagulability, stasis
of blood flow, and venous endothelial injury, collectively
known as the “Virchow’s Triad” of pro-coagulant risk,
are major factors in the pathophysiology of DVT. More
recently, it has become apparent that susceptibility to
venous disease is also governed by a complex interplay
of gene expression, inflammation, lipid biology, and other
processes. Because these processes remain incompletely
characterized, standard treatment for DVT remains fo-
cused upon reducing recurrent events via the use of anti-
coagulant drugs.
Patients with venous thromboembolism (VTE) are gen-
erally managed with anticoagulant therapy with the aim of
treating the acute event and preventing death due to
pulmonary embolism (PE), in addition to minimizing the
risk of postphlebitic symptoms and recurrent VTE. For
most patient groups, initial therapy consists of administra-
tion of a parenteral anticoagulant drug with subsequent
transition to long-term therapy with an oral vitamin K
antagonist (VKA) such as warfarin for at least 3 months.
Determination of the appropriate warfarin dose during
initiation and maintenance therapy requires an under-
standing of patient factors that influence dose response:
age, body weight, nutritional status, acute and chronic
disease states, and changes in concomitant drug therapy
and diet [4].
The goal with warfarin therapy is to maintain a balance
between prevention of recurrence and excessive bleeding.
This balance requires careful monitoring, typically by
prothrombin time (PT)/International Normalized Ratio
(INR). INR is only applicable for those taking warfarin and
an INR range of 2.0 to 3.0 should be taken as therapeutic
range with 2.5 as a target value for patients with DVT.
INR is, therefore, used to adjust a patient’s drug dosage to
get the PT into the desired therapeutic range that is right
for the patient and their condition. When INR is non-
therapeutic, there are many options for dose adjustments.
Patients whose INR is just outside the therapeutic range
can be managed by either adjusting the dose up or down
in increments of 5 to 20 % based on the cumulative
weekly dose of warfarin or by more frequent monitoring,
the latter with the expectation that the INR will return to
therapeutic levels without a dosage change [5].
Patients receiving anticoagulant drugs such as DVT
patients must be carefully screened for DRPs. While
receiving anticoagulants, patients must be monitored
closely to ensure effectiveness and to prevent side effects
or overdosing. Hence, it has narrow therapeutic rangesand is associated with a high rate of DRPs thus failing
to monitor warfarin therapy could increase the risk of
recurrent thrombosis and hemorrhagic complications.
Therefore, this study was initiated to address the pos-
sible DRPs that could occur in the management of
patients with DVT in the study area.
Methods
The study was carried out at Tikur Anbessa Specialized
Hospital (TASH), Ethiopia’s largest general Public Univer-
sity Hospital. A cross-sectional descriptive study involving
retrospective chart review of patients with objectively di-
agnosed VTE and key informant interview were carried
out. Data of study population were abstracted from med-
ical record charts of patients with objectively diagnosed
VTE who visited the hospital from July 2012 to June 2013,
using structured data collection format. Data abstracted
included the following fields: patients’ demographics, dos-
age schedule of the objective medications, type and num-
ber of concomitantly prescribed medications, number and
types of concurrent medical conditions, series of patients’
INR values and others related conditions. For the key
informant interview, 3 physicians (2 hematologists and 1
consultant internist) who had long experience in the man-
agement of DVT and were working in the Hematology
unit of TASH were interviewed. The data obtained from
the interview included: the treatment guideline on which
current DVT management depends in the study setting,
factors need to be considered in deciding dose adjust-
ments for a given nontherapeutic INR values; instructions
regarding foods rich in vitamin K intake while patients are
on anticoagulation therapy and other related factors.
Statistical analysis
Data entering and analysis were performed using SPSS
software version 16.0. Descriptive statistics was calculated
for demographic and clinical characteristics of patients.
The percentage of warfarin dose change was calculated by
dividing the difference of the total weekly dose before and
after the time of adjustment by the total weekly dose
before the time of adjustment and multiplying the quo-
tient by 100 %. The association of the dosage change and
the consequent change in INR value was done by simple
linear regression analysis and the coefficient of determin-
ation (r2 value) was taken to determine the relationship
between the variables at 95 % CI and p-value < 0.05
was taken as statistically significant association. Cross-
tabulation was performed for a 2x2 variables and Chi-
square statistic (χ2) was calculated to show the association
between the variables at 95 % CI.
Ethical clearance
Prior to data collection, the study proposal was approved
by the Ethical Review Board (ERB) of School of Pharmacy
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Addis Ababa University. During data collection, name of
the patients was excluded and record card numbers were
used. Data analysis was performed using a code number
that had been given to each patient data collection instru-
ment. Hence, confidentiality of all information obtained
from the patient’s medical record cards were kept and
respected. Before conducting the interview, informed con-
sent was obtained from the physicians.Results
The study included 91 patients: 87.9 % with DVT, 4.4 %
with PE, and 7.7 % with combined PE and DVT. Fifty
three (58.2 %) were females. Mean age was 38.6 years
(±13.76 years) and the age ranged from 16 to 70 years
and more than 2/3 of the study population (69.2 %)
was below age of 44 years. The most common concurrent
medical condition was cancer. Thirty eight (41.8 %) pa-
tients were prescribed with warfarin and other medi-
cations concurrently that might potentially alter INR
(Table 1).Table 1 Demographic and clinical characteristics of patients
with DVT (n = 91)
Patient characteristics n (%)
Sex Female 53 (58.2)
Male 38 (41.8)















Less than 3 55 (60.4)
Greater or equal to 3 36 (39.6)
Number of patients with
concomitant drugs (n = 38)
Drugs that ↑INRb 21 (55.3)
Drugs that ↓INR 13 (34.2)
Drugs that ↑ or ↓INR 4 (10.5)
aHIV/AIDS: Human Immunodeficiency Virus/Acquired
Immunodeficiency Syndrome
bINR: International normalized ratio
cOthers include venous insufficiency, pulmonary tuberculosis, heart failure,
diabetes mellitus, and dyslipidemiaWarfarin dose and INR
A total of 415 INRs were recorded over 12 months
and “percent of measured INRs in range” was used to
obtain the time in therapeutic range. Patients spent
49.2 %, 33.5 % & 17.3 % of time in subtherapeutic,
therapeutic & supratherapeutic INR ranges, respect-
ively (Fig. 1).
More than 66 % (276/415) of INR values were nonthera-
peutic and appropriate for warfarin dose adjustment,
although clinical judgment might also be considered.
Accordingly, the average daily dose of warfarin was
increased, unchanged and decreased for 95 (46.6 %),
102 (50 %) and 7 (3.4 %) of subtherapeutic INR values, re-
spectively. The average daily dose of warfarin was increased,
unchanged and decreased for 3 (4.2 %), 25 (34.7 %)
and 44 (61.1 %) for supratherapeutic INR ranges, re-
spectively (Table 2).
The daily maintenance dose of warfarin before and
after adjustment differed greatly between individuals; it
was commonly between 1.25 mg/day and 12.5 mg/day
during both periods. The average maintenance dose dur-
ing the specified period was about 5.7 mg/day before and
5.4 mg/day after dose adjustment. The dose was lower in
the elderly, which was 4.2 mg/day before and 2.5 mg/day
after dosage change.
Effect of warfarin dose on the value of INR values was
analyzed based on American College of Chest Physicians
(ACCP) guideline [5]. Dose adjustment should be made
based on the recent or current INR value and the previous
cumulative weekly dose of warfarin. There had to be sub-
sequently documented INR value at least for one week
and within two months (56 days) following the dosage
change to know the effect of dose. In this study, only
13.4 % (37/276) of nontherapeutic INRs were considered
according to the above recommendation. Therefore, ana-
lysis of the effect of warfarin dose was performed for 41
patients. Among these, warfarin dosage was adjusted for
more than 90 % of non-therapeutic and for about 10 % of
therapeutic INRs (Fig. 2).Association of warfarin dose and INR values
Adjustment of warfarin dose up or down was done in
increments of 16 to 100 % for recent subtherapeutic
INRs, 16 to 50 % for therapeutic and 11 to 66 % for
overtherapeutic INRs with mean of 36.5 (±18.03) based
on the cumulative weekly dose of warfarin. There was a
moderate linear relationship between percentage of
dosage adjusted and consequent INR values, which
was statistically significant (R2 = 0.419; p = 0.000). This
analysis revealed that about 42 % of the variations in INR
values were explained by changes in warfarin dosage.
Accordingly, 21(51.2 %) of them had a non-therapeutic
INR range following dosage adjustment (Table 3).
Fig. 1 Time spent in different International Normalized Ratio ranges in patients on warfarin therapy. A series of all recorded International Normalized
Ratio (INR) values were collected over 12 months for each patient and calculated to determine whether they are in therapeutic range or not while on
anticoagulation therapy
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Drug interaction with warfarin
More than 18 potentially interacting drugs were pre-
scribed concomitantly with warfarin for 38 patients.
Among these, 4 drugs were categorized as major interac-
tions which are known to potentiate or inhibit warfarin
effect by altering INR and 14 drugs as moderate inter-
action [6, 7] (Table 4). As a result, more than 55 %
(21/38) and 34 % (13/38) of patients were prescribed
with drugs that might increase and decrease INR when
administered with warfarin, respectively (Table 1).
Among the patients whose warfarin dosage was ad-
justed, 46.3 % (19/41) of them were taking other medica-
tions during dosage adjustment that would have potential
interaction with warfarin. This potential interaction ap-
peared to contribute to fluctuation of INR values, as the
values were out of range in a relatively higher proportion
of (58 %) patients. Among the 22 patients that potential
drug interaction was not a concern, INR was out of range
in 45.5 % of the cases. Comparison was made between the
two groups that had out-of-range INR to establish the
relationship between drug-interaction and INR values.









INR < 2 7 (3.4) 102 (50) 95 (46.6) 204 (100)
INR > 3 44 (61.1) 25 (34.7) 3 (4.2) 72 (100)difference (OR = 1.65, p = 0.43), indicating the lack of
association between the two factors (Fig. 3).
Food interaction with warfarin
Information about food interaction with warfarin was
insufficiently documented except one instruction related
to foods containing vitamin K. Thus, more than 12 %Fig. 2 Recent International normalized ratio for which warfarin dose
was changed (n = 41). Effect of warfarin dose adjustment on the
value of INR values was analyzed. Based on recommendations (ACCP
2008), analysis of the effect of warfarin dose was performed for 41
patients for those subsequently documented INR values at least for
one week and within two months following the dosage change exists
Table 3 Percentage range of warfarin dose adjusted and its









Less than 1.5 8 (19.5) 25–50 (37.5)↑ 1.5–1.9 2 (25)
2.0–3.0 5 (62.5)
>4.0 1 (12.5)




2.0–3.0 4 (9.8) 16–50 (33)
(1 case = 16 %↑;
3 cases = 20-50 %↓)
< 1.5 1 (25)
1.5–1.9 2 (50)
2.0–3.0 1 (25)
3.1–4.0 8 (19.5) 11–33 (22)↓ < 1.5 2 (25)
1.5–1.9 2 (25)
2.0–3.0 4 (50)
4.1–5.0 4 (9.8) 16–66 (41)↓ < 1.5 1 (25)
1.5–1.9 1 (25)
2.0–3.0 2 (50)
5.1–9.0 5 (12.2) 20–66 (43)↓ < 1.5 1 (20)
1.5–1.9 3 (60)
2.0–3.0 1 (20)
Fig. 3 Potential drug interaction at the time of warfarin dose
adjustment and consequent INR value (n = 41)
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tion were instructed to avoid green leafy vegetables (rich
in vitamin K) during their anticoagulation treatment.Adherence to warfarin treatment
Possible causes of non-adherence to anticoagulation treat-
ment were documented in 6.6 % of the studied population
and the most common was missing doses (4 of 6 possibleTable 4 Types of drugs concurrently prescribed with warfarin
known to have interaction and their potential effect on INR
values (n = 91)
Drugs Effect on INR Severity
Norfloxacin, Metronidazole, Clarithromycin Increase Major
Rifampin Decrease Major
Isoniazid, Omeprazole, Tramadol, Ceftriaxone,
Cimetidine, Allopurinol, Azithromycin
Increase Moderate
Nevirapine, Neurobion, Mercaptopurine Decrease Moderate






Hydrochlorothiazide Decrease Minorcauses) and the rest is related to availability of the product.
Three of four patients with documented non-adherence
had a nontherapeutic INR range.ADR associated with warfarin therapy
About 9 % of patients who were on anticoagulation medi-
cation were documented to experience minor bleeding
events (Fig. 4).Discussions
Warfarin dose adjustment was performed for nonthera-
peutic INR values (more than 66 % of total INR values).
Among these, warfarin dose was decreased in 3.4 % of
subtherapeutic INRs and increased in 4.2 % of suprathera-
peutic INR ranges, although there was no clear reason
documented for such paradox. In addition, the dose
adjustments of only 13.4 % of nontherapeutic INRs were
dependent on the recent INR values and cumulative
weekly doses of warfarin, as recommended by ACCP
guideline [5]. These imply that, most of anticoagulation
management might have done by clinical evaluation of the
patients’ conditions. Although this approach have para-
mount importance, it would be much better if supported
by available valid guidelines. Such practices might not
allow someone to know the direct effect of changes in
medication dose and might result in suboptimal quality
Fig. 4 Prevalence of ADR associated with warfarin (n = 91)
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strated by the low time patients stay in therapeutic INR
range (33.5 %). Hence, the percentage of INRs in thera-
peutic range highly depends on the quality of dose
management [5].
Among patients for which analysis of the effect of
warfarin dose on the value of INR values was performed,
nearly 10 % of INR values for which warfarin dosage had
been adjusted were in the therapeutic range. The key
informants stated that although dosage changes should
be done based on the state of INR, patients’ conditions
were taken into account. For example, for patients with
certain conditions such as peptic ulcer and other condi-
tions of bleeding events, the risk-benefit ratio would be
considered and dosage changes might be done accord-
ingly, even if the INR values were within the therapeutic
range. According to other studies, dosage change is not
recommended for therapeutic INR values [8], for a single
INR that is slightly out of range [9, 10]. ACCP guidelines
also do not support dosage change for therapeutic INRs
[5]. Therefore, it is important to consider the standard
guidelines while deciding to modify/adjust the mainten-
ance anticoagulant doses.
Warfarin weekly dose change ranged between 16 to
100 % for recent subtherapeutic INRs, 16 to 50 % for
therapeutic and 11 to 66 % for overtherapeutic INRs.
But, according to ACCP guidelines, patients whose INR
is just outside the therapeutic range can be managed by
either adjusting the dose up or down in increments of 5
to 20 % [5]. Other studies also recommended that
dosage changes should be altered by the total weekly
dose of 5 to 20 % [8, 9, 11, 12]. Variability in the amount
or percentage of warfarin dosage change might be due
to the absence of local dosing protocol or failure to adhere
to the available international guideline. It is important
to adhere to the international standard treatment
guidelines where there are no local treatment protocolswhile deciding to modify/adjust the maintenance anti-
coagulant dosages for nontherapeutic INR values. Institu-
tional protocols for dosing decisions during maintenance
VKA therapy should be developed and used accordingly
in order to minimize consequences of DRPs in patients
with DVT.
In the present study, change in warfarin dose up or
down showed significant linear relationship with conse-
quent INR values (p = 0.000). Accordingly, about 42 % of
the variations in INR values were accounted for by war-
farin dosage change. As a result, percentage of weekly
warfarin dosage reduction (up to 70 %) was related to
the consequent nontherapeutic low INR values. There-
fore, dose reductions might be one of the reasons for
low INRs and dosage changes especially higher dose
reductions could be major DRPs that might expose the
patients to high risk of recurrent thrombosis complica-
tions. As evident from the current finding, more than
12 % were presented with significantly under-therapeutic
INR range (INR less than 1.5) at weekly warfarin dose
reduction of 21–70 %. This finding is in agreement with
reports of different studies that, response to a previous
change in warfarin dosage was the cause of under-
anticoagulation [13] and low INR values [10, 14]. There-
fore, high dosage changes greater than 20 % are not
advisable and should be avoided in order to minimize
complications such as recurrent thrombosis. But, there
might be exceptions that need special considerations of
higher doses including concurrent medications such as
amiodarone and rifampin which need a total weekly dose
reduction and increment of 50 %, respectively [15].
Five (12.2 %) patients presented with over-therapeutic
INRs at weekly warfarin dosage increment ranging from
11 to 100 %. This might increase the risk of overanticoa-
gulation and thus expose the patients to high risk of
bleeding complications as supported by different studies
[13, 16]. Dosage increment greater than 20 % should be
avoided especially as the dosages become increased
more than 40 % the risks might be more. There were 3
cases (7.3 %) in the current study that presented with an
INR value greater than 4.0 at greater than 40 % dosage
increment. It was not possible to say anything about
these patients, as there were no documented adverse
events except for some minor undesirable effects (9 %)
such as nasal and vaginal bleeding, which were said to
be not related to the above factor. But, INR values greater
than 3.3 were recorded at the time of these bleeding
events although there was no recent dose adjustment
done that allows us to correlate with warfarin overdose.
Nevertheless, the risk of bleeding should be an issue of
utmost importance. Therefore, these trends should be
guided by valid treatment guidelines in order to improve
clinical outcomes and minimize unwanted complications
due to anticoagulant drug overdose.
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potential interactions that could make INR to fall out of
the therapeutic range. About 42 % of patients received
warfarin concomitantly with 18 other medications that
have potentially major or moderate interaction with
warfarin. For more than 46 % (19/41) of patients, co-
administration was made at the time of dosage adjust-
ment. The fact that about 58 % of patients, in which
drug-interaction was a concern, had non-therapeutic
INR range suggests that whenever there is a need for
dosage changes in patients with DVT the concurrent
medications should be considered. It was stated that
for most interactions a total weekly dose adjustment
of either an increase or decrease of 30 % is needed
except for certain drugs such as amiodarone and rifampin
which need a total weekly dose reduction and increment
of 50 %, respectively [15]. But, in the present study, both
dose reductions and increments were done up to 50 %
regardless of the type of concurrent medications and this
might expose the patients to the risk of recurrent or
hemorrhage complications.
Norfloxacin and metronidazole were prescribed for only
one and two patients who were on warfarin, respectively.
In both cases an increased INR value was showed but no
apparent risk of bleeding since the increment was from
low to therapeutic INR range. But one study reported that,
metronidazole had shown an impact on bleeding risk
when used with warfarin concomitantly [17]. In another
study, all patients who received quinolone antibiotics con-
comitantly with warfarin had INR values above 3.5, sug-
gesting drug-induced warfarin potentiation [18]. Rifampin
was prescribed for 2 patients. Out of these, one patient’s
INR was dropped from 1.31 to 1.27 following warfarin
increment of 33 % and the other patient’s INR increased
from 1.33 to 2.1 following warfarin increment of 50 %,
suggesting major drug-drug interaction and need of large
increment of warfarin dose. This is supported by a prac-
tice guideline [15], which stated that for rifampin interac-
tions a cumulative weekly dose of warfarin increment of
50 % is needed. Whenever there is a need of anticoagulant
dosage changes in patients with DVT, changes in concur-
rent medications especially those with major interactions
with VKAs should be considered.
Tramadol was reported to increase the risk of bleeding
[17]. In the present study, this drug was prescribed for
17 patients who were on warfarin therapy. Among these,
INR values of 6 patients were increased to suprathera-
peutic ranges suggesting tramadol-induced warfarin po-
tentiation but difficult to generalize since warfarin dose
increment of 20–50 % was performed during this time.
In addition, more than 41 % of tramadol prescriptions
were written on a PRN (as required) basis without speci-
fied maximum daily doses. This might contribute to
unintentional administration of over-dosage (more than400 mg per day) and might also lead to increased effect
of warfarin and its bleeding risk. Thus, it would be help-
ful to write full dosage schedule including the maximum
daily dosage whenever medications are ordered especially
when prescribed on the basis of PRN.
Vitamin K is known to reverse warfarin’s pharmacologic
activity, and many foods containing sufficient vitamin K
reduce the anticoagulation effect of warfarin if a patient
consumes them in large portions or repetitively within a
short period of time. The present study showed that more
than 12 % were instructed to avoid green leafy vegetables
(rich in vitamin K) during their anticoagulation treatment.
Responses from key informants regarding such practice
were taken. Some of them suggested that unexplained
changes in INR records might force to consider absolute
avoidance of diets rich in vitamin K. This was not in
agreement with other report that suggested considering
abrupt changes rather than avoidance [19]. In the con-
trary, other informants said this was not the practice and
strongly underlined to a consistent and moderate intake
of such foods, as also supported by different studies
[20, 21]. One study revealed that changes in dietary
vitamin K intake were among the causes of INRs below
2.0 and above 4.0 [13]. Others also recommended that
patients should be encouraged to maintain consistency in
their vitamin K intake and should strive to meet the
recommended dietary allowance for vitamin K [19, 21]
because dietary content or extent of absorption of vitamin
K might have effect on warfarin [16]. Patients should be
given a list of vitamin K rich foods and encouraged to
maintain consistency in their vitamin K intake rather than
absolute avoidance and alternative sources of vitamin K,
such as multivitamins and nutritional supplements should
also be considered.
It is difficult to assess actual prevalence of patient non-
adherence from medical charts. Regardless of this, some
possible causes of non-adherence were documented in
6.6 % of studied population and the most common was
missing doses. Although three of four patients with docu-
mented non-adherence had a nontherapeutic INR range,
the low number of these cases compared to patients with-
out non-adherence did not allow us to establish a sound
association between non-adherence and INR values. But
literature showed that, noncompliance was the cause of
under-anticoagulation [13, 14]. Ensuring the patients’ un-
derstanding about the benefits of adhering to the prescribed
medications and the consequences of non-adherence to
treatments is crucial in order to achieve the desired thera-
peutic goals. Hence patient compliance can influence the
frequency of long-term INR monitoring [17].
Conclusion
In the present study, although young adults were among
the commonly affected age groups, VTE is becoming the
Daba et al. BMC Hematology  (2016) 16:2 Page 8 of 8major cause of concern in all age groups. Managing
patients with VTE is more complicated and prone to
different DRPs for several reasons, including variable
nature of anticoagulants such as warfarin, co morbid-
ities, concurrent medications and other factors related
to patients. In this study, different DRPs were identi-
fied and the most frequent were sub-therapeutic doses,
over-therapeutic doses, and potential drug interactions,
highlighting the importance of considering drugs as a
possible cause of health problems and the need for their
rational use. Warfarin dose adjustment can complicate the
treatment course because it demands the knowledge of
different factors. Thus, higher dosage changes were among
the reasons for non-therapeutic INR values as one of the
major DRPs that might expose patients to high risk of
recurrent and hemorrhagic complications.
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